COX-2: where are we in 2003? Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients

被引:8
作者
Hochberg, MC [1 ]
机构
[1] Univ Maryland, Sch Med, Div Clin Immunol & Rheumatol, Baltimore, MD 21201 USA
关键词
celecoxib; COX-2 selective inhibitors; osteoarthritis; rheumatoid arthritis; rofecoxib;
D O I
10.1186/ar617
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cyclooxygenase ( COX)-2 selective inhibitors have been shown to have comparable efficacy to nonselective nonsteroidal anti-inflammatory drugs ( NSAIDs) in the treatment of patients with osteoarthritis (OA) and rheumatoid arthritis ( RA). Large outcome studies have shown that patients with OA and RA not taking low-dose aspirin have fewer symptomatic and complicated upper GI events when treated with COX-2 selective inhibitors than with nonselective NSAIDs. When used in recommended dosages, there is no convincing evidence that patients treated with COX-2 selective inhibitors have an increased incidence of cardiovascular thrombotic events, including non-fatal myocardial infarction, than patients treated with either placebo or nonselective NSAIDs other than naproxen. Co-therapy with low-dose aspirin is recommended in patients with OA and RA at increased risk for cardiovascular events; the need for gastroprotective therapy in such patients is controversial.
引用
收藏
页码:28 / 31
页数:4
相关论文
共 28 条
[11]  
Hochberg MC, 2001, CLIN EXP RHEUMATOL, V19, pS15
[12]   Are selective COX 2 hihibitors superior to traditional non steroidal anti-inflammatory drugs?: Adequate analysis of the CLASS trial indicates that this may not be the case [J].
Jüni, P ;
Rutjes, AWS ;
Dieppe, PA .
BRITISH MEDICAL JOURNAL, 2002, 324 (7349) :1287-1288
[13]   Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function [J].
Komhoff, M ;
Grone, HJ ;
Klein, T ;
Seyberth, HW ;
Nusing, RM .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1997, 272 (04) :F460-F468
[14]   Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib [J].
Konstam, MA ;
Weir, MR ;
Reicin, A ;
Shapiro, D ;
Sperling, RS ;
Barr, E ;
Gertz, BJ .
CIRCULATION, 2001, 104 (19) :2280-2288
[15]  
Lanza FL, 1998, AM J GASTROENTEROL, V93, P2037
[16]  
Matsumoto AK, 2002, J RHEUMATOL, V29, P1623
[17]   COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease [J].
Ray, WA ;
Stein, CM ;
Daugherty, JR ;
Hall, K ;
Arbogast, PG ;
Griffin, MR .
LANCET, 2002, 360 (9339) :1071-1073
[18]   Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetane) [J].
Reicin, AS ;
Shapiro, D ;
Sperling, RS ;
Barr, E ;
Yu, QF .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02) :204-209
[19]   Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women [J].
Rodríguez, LAG ;
Varas, C ;
Patrono, C .
EPIDEMIOLOGY, 2000, 11 (04) :382-387
[20]  
Scheiman JM, 2002, CLEV CLIN J MED, V69, P40